Bolus markets are markets for new drugs where unmet need is extremely strong and clinical benefit from the new drug dramatically improves standard of care. Since bolus markets have an intense and high ...

Across multiple types of GI cancers, patients who did not receive bolus 5-FU had overall survival that was almost identical to that of patients who did receive the bolus (HR 0.99, 95% CI 0.91-1.07).

Individuals who received the bolus had an increased likelihood of developing neutropenia (22.7% vs. 10.7%; P < .01) or thrombocytopenia (16.1% vs. 11.2%; P < .01) in the 14 days after treatment.

Clinical Investigation Published: 08 April 2014 Bolus vs. continuous feeding: effects on splanchnic and cerebral tissue oxygenation in healthy preterm infants Luigi Corvaglia, Silvia Martini ...